Figure S1 (related to Figure 1). Sequence Alignment of the Helicase
Figure S1 (related to Figure 1). Sequence Alignment of the Helicase

Domains of ZRANB3 and SMARCAL1
Similar amino acid residues are shown in red. The alignment was performed using ClustalW. 
3
(B) Time course of the recruitment of GFP-SMARCAL1 to laser-generated stripes.
The experiment was performed as described in (A).
(C) Localization of the APIM motif of ZRANB3 to damage sites. U2OS cells expressing a WT or mutant APIM motif of ZRANB3 fused to a GFP tag and a nuclear localization sequence were UV microirradiated and stained with anti-GFP (green) and anti-γH2AX (red) antibodies and with DAPI (blue). Cells expressing WT GFP-APIM are shown with or without PCNA siRNA treatment before microirradiation.
(D) Graphical representation of the percentage of U2OS cells that display colocalization of GFP-APIM with γH2AX at laser-generated stripes. The data represent the average and standard deviation of three independent experiments. (100 nM) in a time course reaction as in Figure 7E .
(C) Disruption of preformed RAD51-containing D loop structures by SMARCAL1
(25 nM) in a time course reaction as in Figure 7E .
(D) Stability of RAD51-ssDNA nucleofilaments in the presence of WT or mutant ZRANB3 and SMARCAL1 proteins (100 nM).
Supplemental Experimental Procedures
DNA Clones
The Gateway entry vector pDONR201-ZRANB3 was purchased from Open
Biosystems ( The Gateway entry vector pDONR223-NZF-mutant was generated from pDONR223-NZF by introducing the NZF mutation described above. The mammalian expression vectors pMSCV-GFP-ZRANB3, pMSCV-GFP-ZRANB3-PIP, pMSCV-GFP-ZRANB3-APIM, pMSCV-GFP-ZRANB3-PIP+APIM, pMSCV-FLAG-HA-ZRANB3, pMSCV-FLAG-HA-ZRANB3-PIP+APIM, pMSCV-FLAG-HA-ZRANB3-NZF were obtained by Gateway recombination between pDONR201-ZRANB3, pDONR201-ZRANB3-PIP, pDONR201-ZRANB3-APIM, pDONR201-ZRANB3-PIP+APIM, pDONR201-ZRANB3-NZF and pMSCV-GFP or pMSCV-FLAG-HA. pMSCV-FLAG-HA-ZRANB3, pMSCV-FLAG-HA-ZRANB3-PIP+APIM and pMSCV-FLAG-HA-ZRANB3-NZF contain a doxycycline inducible promoter.
The mammalian expression vectors pMSCV-GFP-APIM and pMSCV-GFP-APIMmutant were obtained by Gateway recombination between pDONR223-APIM, pDONR223-APIM-mutant and pMSCV-GFP. The Gateway entry vector pDONR223-SMARCAL1 and the expression vector pMSCV-GFP-SMARCAL1
have been previously described (Ciccia et al., 2009 ). The bacterial expression vectors pET60-NZF and pET60-NZF-mutant were obtained by Gateway recombination between pDONR223-NZF, pDONR223-NZF-mutant and pET60-DEST (Novagen). The baculoviral vectors pFASTBAC-FLAG-ZRANB3 and pFASTBAC-FLAG-SMARCAL1 were generated by cloning ZRANB3 or SMARCAL1, which were PCR amplified with a forward primer containing the FLAG tag sequence, into the EcoRI and XhoI sites of pFAST-BAC1 (Invitrogen).
The baculoviral vectors pFASTBAC-FLAG-ZRANB3-PIP+APIM and pFASTBAC-FLAG-ZRANB3-NZF were generated by site directed mutagenesis of pFASTBAC-FLAG-ZRANB3 by introducing the mutations in the PIP box and APIM motif or in the NZF motif described above. The baculoviral vectors pFASTBAC-FLAG-ZRANB3-HD and pFASTBAC-FLAG-SMARCAL1-HD were generated from pFASTBAC-FLAG-ZRANB3 or pFASTBAC-FLAG-SMARCAL1
by site directed mutagenesis of the amino acid sequence DE to AA (amino acids 157-158 or 549-550 of ZRANB3 or SMARCAL1, respectively).
Protein Purification
Sf9 insect cells (1 x 10 8 cells) were harvested 3 days after infection with baculoviruses expressing FLAG-ZRANB3, FLAG-ZRANB3-HD, FLAG-SMARCAL1 and FLAG-SMARCAL1-HD. Cell pellets were resuspended in 2 ml of buffer A (50mM Tris pH 7.6, 0.01% NP40, 1 mM EDTA, 10% glycerol)
supplemented with 150 mM KCl, Cytobuster (1:5 dilution, EMD4Bioscience), phosphatase inhibitors cocktail set I and II (Bd Pharmigen) and protease inhibitors (Roche). Cell lysates were gently rocked for 30 min at 4°C and then centrifuged at 14,000 rpm for 15 min. Cell pellets were then resuspended in 1 ml of buffer A supplemented with 500 mM KCl, sonicated (2 x 20 sec) and rocked for 1 h at 4°C. After centrifugation, the low and high salt extracts were mixed and the salt concentration was adjusted to 100 mM KCl. The cell lysate was loaded onto a 0.5 ml CM sepharose (Pharmacia) column, which was then washed with 3 x 10 ml of buffer A containing 100 mM KCl. Proteins were eluted in buffer A supplemented with 500 mM KCl (6 x 0.5 ml elutions), the fractions containing the proteins of interest were combined and the salt concentration was adjusted to 200 mM KCl. FLAG-tagged proteins were then immunoprecipitated overnight using 20 µl of EZview red anti-FLAG M2 beads (Sigma). Immunoprecipitated proteins were then washed 4 times with buffer A containing 200 mM KCl and then eluted with 3 x 50 µl of buffer B (50 mM Tris pH 7.5, 100 mM KCl, 10% glycerol) supplemented 3X FLAG peptide (500 µg/ml, Sigma) by gently rocking for 10 min at room temperature. Eluted proteins were stored at -80°C.
Purification of PCNA and its in vitro poly-ubiquitination reaction were performed as previously described (Unk et al., 2008) . RecA and human RAD51 were purified according to published protocols (Mirshad and Kowalczykowski, 2003; Sigurdsson et al., 2001 ).
In Vitro Pulldowns
E. coli BL21 (DE3) bacteria (100 ml) carrying pET60-NZF or pET60-NZF-mutant were grown at 30°C to OD 600 = 0.3 and induced for 5 h with 0.1 mM IPTG. Cell pellets were resuspended in 1.5 ml of GST buffer (50 mM Tris ph 7.5, 500 mM NaCl, 1% Triton, 1 mM DTT, 10% glycerol) supplemented with 10 mg/ml lysozyme, Bugbuster (10X, EMD4Bioscience) and protease inhibitors (Roche).
Following sonication (2 x 30 sec), cell lysates were centrifuged at 14,000 rpm for 20 min. Supernatants were then incubated with 50 µl of glutathione beads (GE Healthcare) for 2 h at 4°C and the beads were then washed 5 times with GST buffer. Glutathione beads bound to GST-NZF or GST-NZF-mutant (approx. 5 µg)
were incubated with mono-ubiquitin, K48-or K63-linked poly-ubiquitin chains (1 µg, Boston Biochem) in 100 µl of binding buffer (50 mM Tris ph 7.5, 150 mM NaCl, 0.1% Triton, 10% glycerol). Following gentle rocking for 3 h at 4°C, beads were washed 4 times with binding buffer and the proteins bound to GST-NZF or GST-NZF-mutant were analyzed by gel electrophoresis and western blotting.
Sf9 insect cells (1 x 10 8 cells) were harvested 3 days after infection with baculoviruses expressing FLAG-ZRANB3, FLAG-ZRANB3-PIP+APIM or FLAG-ZRANB3-NZF. Cell pellets were lysed and FLAG-tagged proteins were pulled down with EZview red anti-FLAG M2 beads (Sigma) as described in the protein purification section. Anti-FLAG beads bound to FLAG-ZRANB3, FLAG-ZRANB3-PIP+APIM or FLAG-ZRANB3-NZF were incubated with purified unmodified PCNA (0.6 µg) or with a mixture of unmodified PCNA (0.6 µg) and polyubiquitinated PCNA (1.2 µg) in 100 µl of FLAG binding buffer (50 mM Tris ph 8, 400 mM NaCl, 10% glycerol, 0.1% triton). After 4 h of gentle rocking at 4°C, beads were washed 4 times with FLAG binding buffer and then proteins bound to FLAG-ZRANB3, FLAG-ZRANB3-PIP+APIM or FLAG-ZRANB3-NZF were analyzed by gel electrophoresis and western blotting.
Cell Culture
The human osteosarcoma cell line U2OS and human embryonic kidney fibroblast 
Cell Competition Assay
Cell competition assay was performed essentially as previously described (Smogorzewska et al., 2007) . In particular, parental U2OS cells or U2OS cells Microirradiation experiments were performed as previously described (Ciccia et al., 2009 ). For foci experiments, U2OS cells expressing GFP-ZRANB3 were treated with 2 mM hydroxyurea, 50 nM camptothecin, 5 µM cisplatin, 300 nM mitomycin C for 12 h or UV irradiated (25 J/m 2 ) and cells were fixed and stained 6-8 h after washout of the drug or irradiation. UV irradiated cells were treated with 2mM caffeine or with ATM inhibitor (10 µM, Calbiochem, KU55933) and ATR inhibitor (2 µM, VE-821) (Reaper et al., 2011) 8 h before and 2-6 h after irradiation. Cells treated with USP1 siRNA (50 nM) were fixed and stained 3 days after siRNA transfection. For RAD51 foci staining, cells were treated for 1 h with camptothecin (10 nM), fixed 6-12 h after washout of the drug and stained with mouse monoclonal anti-RAD51 antibody (Abcam, ab213).
Immunoprecipitation of Protein Complexes
Stable 293T-Rex (1 x 10 7 cells) with inducible expression of FLAG-ZRANB3 or U2OS cells (5 x 10 6 cells) stably expressing FLAG-ZRANB3 were transfected with control or USP1 siRNA (20 nM). After 72 h, 293T-Rex cells were treated for 24 h with 2 µg/ml doxycycline to induce the expression of FLAG-ZRANB3.
Caffeine (2 mM) was added 12 h before UV irradiation (30 J/m 2 ) and cells were harvested 4 h after irradiation. Cells were then fixed in 10 ml of 0.25% or 1% (for 293T-Rex or U2OS cells, respectively) formaldehyde (diluted in PBS) for 10 min at room temperature and the reaction was stopped by addition of glycine (0.125 M final concentration). After 2 washes of the cell pellet with PBS, cells were resuspended in 1 ml of TE buffer (10 mM Tris pH 8, 1 mM EDTA) with 1% SDS.
Following centrifugation at 3000 rpm for 5 min, pellets were washed twice with 2 ml of TE buffer. Pellets were then resuspended in 1 ml of TE buffer containing 0.1% SDS and protease inhibitors and were sonicated with the Bioruptor Sonicator (10 x 30 sec). Lysates were then centrifuged at 14,000 rpm for 10 min and the supernatant was supplemented with 150 mM NaCl and 0.1 % NP-40.
Protein complexes were then immunoprecipitated with EZview red anti-FLAG beads (5 µl) overnight at 4°C. Anti-FLAG beads were then washed 5 times with wash buffer (10 mM Tris pH 8, 1 mM EDTA, 0.1% NP40, 150 mM NaCl) and washes with dilution buffer, protein crosslinks were reversed and proteins analyzed as described above.
In Vitro Assays
Fork Regression Assay. Fork regression assays were performed in reaction buffer (20 mM Tris pH 7.5, 0.1 mg/ml BSA, 1 mM DTT, 10% glycerol, 5 mM ATP, 5 mM MgCl 2 ) supplemented with 100 mM or 50 mM NaCl in the presence of ZRANB3 or SMARCAL1 (50 nM), respectively, together with 32 P-labeled synthetic fork (0.5 nM) or plasmid based fork (5 nM) substrates. Description of the fork substrates and the experimental details of the assays have been previously provided (Blastyak et al., 2007) .
Preparation of DNA for D loop Assays.
A 100-mer oligodeoxyribonucleotide, complementary to nucleotides 2451-2550 of the minus strand of pUC19, was purchased from Sigma Genosys, and gel purified on a 12% denaturing polyacrylamide gel. The 100-mer was 5'-32 P-labeled using T4
polynucleotide kinase and [γ-32 P]ATP, and purified using MicroSpin G-25 columns (GE Healthcare). Supercoiled pUC19 DNA was purified by non-alkaline lysis followed by cesium chloride density gradient centrifugation (Sambrook, J., V/cm, 2 h) at 4 o C. Following electrophoresis, the gels were dried on DE81 paper
